tbuckley/cabot-search huggingface dataset:
MALT1 Degradation with a Proteolysis-Targeting Chimera for the Treatment of Activated B-Cell Type Diffuse Large B-Cell Lymphoma
Authors: Madhav R Seshadri, Lorena Fontan, Prasanna Sreevatsan, David Scott, John Hatcher, Guangyan Du, Min Xia, Ilkay Us, Nathanael Gray, Ari Melnick
Journal: Blood (2021)
Primary outcome analysis of invasive disease-free survival for monarchE: abemaciclib combined with adjuvant endocrine therapy for high risk early breast cancer
Authors: O'Shaughnessy, JA[O'Shaughnessy, Joyce A.], Johnston, S[Johnston, Stephen], Harbeck, N[Harbeck, Nadia], Toi, M[Toi, Masakazu], Im, YH[Im, Young-Hyuck], Reinisch, M[Reinisch, Mattea], Shao, ZM[Shao, Zhimin], Plk Lehtinen, Huang, CS[Huang, Chiun-Sheng], Tryakin, A[Tryakin, Alexey], Goetz, M[Goetz, Matthew], Rugo, HS[Rugo, Hope S.], Senkus, E[Senkus, Elzbieta], Testa, L[Testa, Laura], Andersson, M[Andersson, Michael], Tamura, K[Tamura, Kenji], Steger, GG[Steger, Guenther G.], Del Mastro, L[Del Mastro, Lucia], Cox, J[Cox, Joanne], Forrester, T[Forrester, Tammy], Sherwood, S[Sherwood, Sarah], Li, XL[Li, Xuelin], Wei, R[Wei, Ran], Martin, M[Martin, Miguel], Rastogi, P[Rastogi, Priya]
Journal: Cancer Research (2021)
Metabolomics analysis of metabolic patterns in chronic rhinosinusitis with nasal polyps
Authors: Yun Ma, Yi Wei, Xiang Liu, Hua Dang, Hua Zou, Peng Tian, Hua Zhong
Journal: Allergy (2021)

Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
72 Spatial whole transcriptome profiling of the tumor microenvironment in prostate carcinomas
Authors: Naishitha Anaparthy, Valeria Giangarra, Sarah Taylor, Mesruh Turkekul, Stephen Williams, Paulius Mielinis, Caroline Gallant
Journal: Journal for ImmunoTherapy of Cancer (2021)

Background Despite years of studies and effort, the best strategies for treating prostate cancer and minimizing the complications of treatment remain unanswered questions. This gap in knowledge is partially due to the inability to dissect the complex heterogeneous tumor microenvironment (TME) and immune compartment. Spatially resolved molecular profiling of tumor sections will enhance our understanding of these complexities; However, it has been particularly challenging to do spatial molecular profiling in formalin-fixed paraffin-embedded (FFPE) tissues due to RNA degradation associated with this tissue-embedding method, which is routinely used in oncology workflows. The 10x Genomics Visium Spatial Gene Expression Solution for FFPE tissue overcomes these limitations, enabling spatial gene expression analysis of FFPE tissues combined with classical histology staining techniques such as Hematoxylin &amp; Eosin (H&amp;E) staining and immunofluorescence. Methods We used the 10x Genomics Visium Spatial Gene Expression Solution for FFPE tissue to analyze and resolve tumorigenic profiles in sections of normal and adenocarcinoma prostate samples. This assay incorporates ~5,000 molecularly barcoded, spatially encoded capture probes in spots over which the tissue is placed, imaged, and permeabilized. Imaging and sequencing data are processed together, resulting in a spatially resolved transcriptional readout. Results We profiled the whole transcriptome in normal, invasive adenocarcinoma, and acinar cell carcinoma FFPE human prostate tissues. Unsupervised clustering of the whole transcriptome data from normal, invasive adenocarcinoma, and acinar cell prostate carcinoma FFPE sections enabled the identification of 2 different regions, which had a well defined spatial distribution within the tissues. Well known prostate gland and prostate-cancer markers were over-expressed in the corresponding healthy and cancerous portions of the tissue, validating the performance of this method. We found that, while in healthy tissues basal cells and luminal cells are spatially organized, this pattern is lost in tumor samples, where luminal cells are greatly expanded in the invasive carcinoma region and do not colocalize with basal cells. Moreover, T lymphocytes are dispersed throughout the whole tissue section in the adenocarcinoma, while plasma B cells are located in the peritumoral region which could impact prognosis. Conclusions Spatial whole transcriptome analysis opens new opportunities for better understanding the TME which can not only help discover novel predictive tumor biomarkers, but also enable identifying cell type and tumor region specific drug targets.
Assessment of Serology after Sars-Cov-2 Vaccine in Allogeneic HCT Recipients
Authors: Melissa Baker, Maria Cortes, Jaeil Ahn, Michele L. Donato, Sukhdeep Kaur, Hyung C. Suh, Alison Morawski, Phyllis McKiernan, Amy Einstein, Michele Boonstra, Scott D. Rowley
Journal: Blood (2021)
Pre-Clinical and Clinical Immunomodulatory Effects of Pomalidomide or CC-92480 in Combination with Bortezomib in Multiple Myeloma
Authors: Chad C Bjorklund, Michael Amatangelo, Hsiling Chiu, Jian Kang, Tiziana Civardi, Jessica Katz, Paulo Maciag, Patrick Hagner, Michael Pourdehnad, Nizar J. Bahlis, Paul G. Richardson, Anjan Thakurta
Journal: Blood (2021)
Co-Occurrence of MDS with MGUS Represents a Unique Disease Entity with Specific Molecular Phenotype and Potential Improved Clinical Outcome
Authors: Tariq Kewan, Ramsha Ahmed, Carmelo Gurnari, Waled Bahaj, Simona Pagliuca, Yogenthiran Saunthararajah, Bhumika J. Patel, Sudipto Mukherjee, Aaron T. Gerds, Anjali Advani, Valeria Visconte, Jaroslaw P. Maciejewski, Hetty E. Carraway
Journal: Blood (2021)
State Laws Permitting Adolescent Consent to Human Papillomavirus Vaccination and Rates of Immunization
Authors: Ashlynn R. Torres, Nicholaus P. Johnson, Mallory K. Ellingson, Caitlin E. Hansen, Carlos R. Oliveira, Linda M. Niccolai, Sangini S. Sheth
Journal: JAMA Pediatrics (2021)

This national cohort study examines National Immunization Survey–Teen to assess the association of adolescents' ability to consent to human papillomavirus vaccination without parental involvement with vaccination rates.
A Novel Method for Highly Efficient Ex Vivo Expansion and Genetic Engineering of Human Natural Killer Cells for Cancer Therapy
Authors: Nobuhiro Kubo, Yudai Murayama, Yasushi Kasahara, Chansu Shin, Minori Baba, Ryosuke Hosokai, Haruko Iwabuchi, Imamura Masaru, Akihiko Saitoh, Chihaya Imai
Journal: Blood (2021)
Assessment of the Effect of Crizanlizumab on Red Blood Cell Adhesion to Endothelial Cells Using a Standardized Endothelium-on-a-Chip Microfluidic Platform
Authors: Erdem Kucukal, Aaron Wolfe, Ryan Kocevar, Lalitha V Nayak, Andreas Bruederle, John Zak, Umut A. Gurkan
Journal: Blood (2021)
Effect of High Intensity Chemotherapy Vs Targeted Therapy on Survival in AML Patients Aged 60-75
Authors: Kieran D Sahasrabudhe, Melanie T Rebechi, Ying Huang, Greg K. Behbehani, Bhavana Bhatnagar, James S. Blachly, Bradley W Blaser, Uma Borate, Ramiro Garzon, Tamanna Haque, Karilyn Larkin, Meixiao Long, Alice S. Mims, Ayman Saad, Sumithira Vasu, Alison R. Walker, Sarah A Wall
Journal: Blood (2021)
Preliminary Results from a Phase Ib Study Exploring MDM2 Inhibitor Siremadlin (HDM201) in Combination with B-Cell Lymphoma-2 (BCL-2) Inhibitor Venetoclax in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (HR-MDS)
Authors: Andrew H. Wei, Massimo Breccia, Melissa Ooi, Maria Teresa Cedena Romero, Fabio Ciceri, Harry P. Erba, Anil Gaur, Romain Sechaud, Ensar Halilovic, Brigitte Kuenzle, Claire Fabre, Kimmo Porkka
Journal: Blood (2021)
A T cell inflammatory phenotype is associated with autoimmune toxicity of the PI3K inhibitor duvelisib in chronic lymphocytic leukemia
Authors: Deepti Gadi, Alec Griffith, Svitlana Tyekucheva, Zixu Wang, Vanessa Rai, Alexander Vartanov, Emily Thrash, Stacey M. Fernandes, Timothy Z. Lehmberg, Brandon Lee, Stephen P. Martindale, John-Hanson Machado, Oreofe Odejide, Philippe Armand, David C. Fisher, Jon Arnason, Matthew S. Davids, James A. Lederer, Jennifer R. Brown
Journal: Leukemia (2021)
Response to Bridging Therapy As a Predictor of Outcomes for Chimeric Antigen Receptor Therapy in Large B-Cell Lymphoma
Authors: Arushi Khurana, Matthew Hathcock, Radhika Bansal, Yucai Wang, Jonas Paludo, Jose C. Villasboas, N. Nora Bennani, Patrick B. Johnston, Stephen M. Ansell, Yi Lin
Journal: Blood (2021)
Abstract 10026: Higher Odds of Major Adverse Cardiovascular and Cerebrovascular Events in Hospitalized Cancer Patients with Hypertensive Crisis: A Nationwide Population-Based Study
Authors: Akhil Jain, Sashwath Srikanth, Nibras Yar Khan, Priya Shenwai, Harika Varma Chintalapalli Patta, Taherunnisa Rida, Ummul Asfeen, Zainab J Gandhi, Rupak Desai
Journal: Circulation (2021)

Background: Cancer patients have an increased risk of new-onset hypertension. Burden, comorbidities, and outcomes of hypertensive crisis (HTNcrisis) in prior and current cancer patients remain undefined. Methods: The National Inpatient Sample (2015 October-2017) was used to identify cancer patients (current+prior cancer) and sub-grouped into HTNcrisis vs. non-HTNcrisis to compare demographics, comorbidities, and outcomes (MACCE-major adverse cardiovascular and cerebrovascular events: all-cause mortality, acute myocardial infarction, cardiac arrest &amp; stroke). Results: Active or prior cancer diagnosis had 9,279,536 admissions, of which 70,530 had HTNcrisis (0.8%). HTNcrisis arm more often included older (74 vs. 71 years), black (22.5 vs. 11.0%), female (58.5% vs. 50.7%), Medicare enrollees (77.2% vs. 67.9%) vs. non-HTNcrisis (Table 1) . HTNcrisis arm had higher rates of hyperlipidemia, smoking, diabetes, renal failure, CHF, prior TIA/stroke, prior CABG vs non-HTNcrisis. Cancer with HTNcrisis had higher rate and odds of MACCE (9.7% vs.19.6%, OR:1.92, 95CI:1.88-1.96), higher rate of AMI (7.6% vs 3.3%), arrhythmia (29.8% vs 27.2%), stroke (10.8% vs 3.0%) with comparable healthcare resource utilization (p&lt;0.001). Of the HTNcrisis cohort, patients with an active cancer diagnosis with prior history of treated cancer (4.9%) had higher all-cause mortality compared to patients with either currently active cancer (4.0%) or prior cancer (2.1%) (p&lt;0.001). Conclusion: Cancer patients with HTNcrisis often included elderly, black, and female compared to those without. HTNcrisis admissions had two times higher odds of MACCE including higher rates of AMI, arrhythmia and stroke. Among HTNcrisis admissions, patients currently diagnosed with active cancer along with prior history experienced a higher burden of inpatient deaths compared to admissions either with current or prior cancer.
Thrombectomy for anterior circulation stroke beyond 6 h from time last known well (AURORA): a systematic review and individual patient data meta-analysis
Authors: Tudor G Jovin, Raul G Nogueira, Maarten G Lansberg, Andrew M Demchuk, Sheila O Martins, J Mocco, Marc Ribo, Ashutosh P Jadhav, Santiago Ortega-Gutierrez, Michael D Hill, Fabricio O Lima, Diogo C Haussen, Scott Brown, Mayank Goyal, Adnan H Siddiqui, Jeremy J Heit, Bijoy K Menon, Stephanie Kemp, Ron Budzik, Xabier Urra, Michael P Marks, Vincent Costalat, David S Liebeskind, Gregory W Albers
Journal: The Lancet (2021)
The KDM5 Family of Histone Lysine Demethylases Are Targets of R-2-Hydroxyglutarate in IDH Mutant Tumors
Authors: Kathryn Gunn, Matti Myllykoski, John Cao, Bill Diplas, Hai Yan, Lucy A. Godley, Peppi Karppinen, Julie-Aurore Losman
Journal: Blood (2021)
A <i>JAK2</i>V617F Variant Allele Frequency Greater Than 50% Identifies Patients with Polycythemia Vera at High Risk for Venous Thrombosis
Authors: Giuseppe Gaetano Loscocco, Paola Guglielmelli, Carmela Mannarelli, Elena Rossi, Francesco Mannelli, Francesco Ramundo, Giacomo Coltro, Silvia Betti, Chiara Maccari, Sara Ceglie, Chiara Paoli, Tiziano Barbui, Ayalew Tefferi, Valerio De Stefano, Alessandro Vannucchi
Journal: Blood (2021)
Case 34-2021: A 38-Year-Old Man with Altered Mental Status and New Onset of Seizures
Authors: Andrew J. Cole, Jonathan E. Slutzman, Edward T. Ryan, Michael H. Lev, George Eng
Journal: New England Journal of Medicine (2021)

A 38-year-old man was evaluated in the emergency department because of altered mental status and a first seizure. Examination revealed an involuntary upward gaze and confusion. Laboratory evaluation revealed leukocytosis and lactic acidosis. A diagnosis was made.
Neutrophil DREAM promotes neutrophil recruitment in vascular inflammation
Authors: Jing Li, Tripti Kumari, Andrew Barazia, Vishwanath Jha, Si-Yeon Jeong, Amber Olson, Mijeong Kim, Bum-Kyu Lee, Vijayprakash Manickam, Zhimin Song, Regina Clemens, Babak Razani, Jonghwan Kim, Mary C. Dinauer, Jaehyung Cho
Journal: The Journal of Experimental Medicine (2021)

The interaction between neutrophils and endothelial cells is critical for the pathogenesis of vascular inflammation. However, the regulation of neutrophil adhesive function remains not fully understood. Intravital microscopy demonstrates that neutrophil DREAM promotes neutrophil recruitment to sites of inflammation induced by TNF-α but not MIP-2 or fMLP. We observe that neutrophil DREAM represses expression of A20, a negative regulator of NF-κB activity, and enhances expression of pro-inflammatory molecules and phosphorylation of IκB kinase (IKK) after TNF-α stimulation. Studies using genetic and pharmacologic approaches reveal that DREAM deficiency and IKKβ inhibition significantly diminish the ligand-binding activity of β2 integrins in TNF-α–stimulated neutrophils or neutrophil-like HL-60 cells. Neutrophil DREAM promotes degranulation through IKKβ-mediated SNAP-23 phosphorylation. Using sickle cell disease mice lacking DREAM, we show that hematopoietic DREAM promotes vaso-occlusive events in microvessels following TNF-α challenge. Our study provides evidence that targeting DREAM might be a novel therapeutic strategy to reduce excessive neutrophil recruitment in inflammatory diseases.
Use of thermal imaging and a dedicated wound‐imaging smartphone app as an adjunct to staging hidradenitis suppurativa
Authors: J.L. Ramirez‐GarciaLuna, S.C. Wang, T. Yangzom, V. Piguet, J.S. Kirby, A. Alavi
Journal: British Journal of Dermatology (2021)

Hidradenitis suppurativa (HS) presents with painful nodules, draining tunnels, abscesses, ulcers, and fistula formation1. Grading systems, (e.g. Hurley Staging System, International Hidradenitis Suppurativa Severity Score System (IHS4), Severity Assessment of Hidradenitis Suppurativa Score (HS-PGA score), and Hidradenitis Suppurativa Area and Severity Index (HASI)) assess disease severity in terms of lesion count, extension and morphology.
Pre-Clinical Efficacy of Targeting TBL1/R-β-Catenin-TCF7L2 Axis Against AML with 3q26 Lesions and EVI1 Overexpression
Authors: Christine Birdwell, Warren C. Fiskus, Christopher Peter Mill, John A. Davis, Arnold Salazar, Courtney D. DiNardo, Koichi Takahashi, Steve Horrigan, Tapan M. Kadia, Kapil N. Bhalla
Journal: Blood (2021)
Chronic Exposure to Cytoreductive Treatment Shapes Clonal Evolution in Myeloproliferative Neoplasms
Authors: Lin-Pierre Zhao, Nabih Maslah, Rafael Daltro De Oliveira, Emmanuelle Verger, Juliette Soret-Dulphy, Clemence Marcault, Nathalie Parquet, Christine Dosquet, William Vainchenker, Emmanuel Raffoux, Stephane Giraudier, Jean-Jacques Kiladjian, Bruno Cassinat, Lina Benajiba, Marine Cazaux
Journal: Blood (2021)
Pilot Implementation of Remote Patient Monitoring Program for Outpatient Management of CAR-T Cell Therapy
Authors: Jonas Paludo, Radhika Bansal, Adam T Holland, Kelsey L Haugen, Megan T Spychalla, Alli L McClanahan, Tuan A Truong, Matthew A Hathcock, Arushi Khurana, Hassan B. Alkhateeb, David Dingli, Suzanne R. Hayman, Prashant Kapoor, Morie A. Gertz, Yucai Wang, Saad S. Kenderian, Taxiarchis Kourelis, Shaji Kumar, Mithun V. Shah, Mustaqeem A. Siddiqui, Rahma M Warsame, Jose C. Villasboas, Nora Bennani, Patrick B. Johnston, Stephen M. Ansell, Tufia C Haddad, Yi Lin
Journal: Blood (2021)
Race Bias in Transcatheter Aortic Valve Replacement
Authors: Clyde W. Yancy, Ajay Kirtane
Journal: JAMA Cardiology (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Impact of HLA Molecular Mismatch on Haploidentical Hematopoietic Stem Cell Transplantation: A Center for International Blood and Marrow Transplant Research Study
Authors: Jun Zou, Tao Wang, Yung-Tsi Bolon, Shahinaz M. Gadalla, Steven G.E. Marsh, Michelle Kuxhausen, Meilun He, Sophie Paczesny, Stephen R. Spellman, Stephanie J. Lee, Stefan O. Ciurea
Journal: Blood (2021)
317 An immunosuppressive tumor population drives global and regional patterns of immune infiltration in heterogeneous tumors
Authors: Miho Tanaka, Lotus Lum, Kenneth Ng, Zoe Adams, Daphne Superville, Melissa Reeves
Journal: Journal for ImmunoTherapy of Cancer (2021)

Background Intratumoral heterogeneity (ITH) is cellular and molecular diversity within a tumor. ITH is linked to failure of immunotherapy in multiple cancer types. One of the suggested mechanisms of this failure is the absence of a productive immune response, which can be driven by the dominance of a tumor population that creates immunosuppressive microenvironment. However, the molecular mechanisms that mediate such dominant immunosuppressive effects and how a dominant immunosuppressive tumor population affects the efficacy of immune checkpoint blockade (ICB) therapy are poorly understood. Methods We generated a library of squamous skin cell carcinoma cell lines derived from DMBA+TPA carcinogen-treated mice. Upon transplantation into immunocompetent mice, two cell lines (CF6 and CF9) gave rise to highly and poorly immune-infiltrated tumors, respectively. These two cell lines were tagged with YFP and RFP, respectively, mixed at a 1:1 ratio and injected subcutaneously. The resulting mixed tumors contained a patchwork of distinct regions that are predominantly occupied with YFP (CF6) cells, occupied with RFP (CF9) cells, or are a mixture of YFP and RFP cells. These mixed tumors were microdissected into YFP, RFP, and mixed regions, and the immune infiltrate in each region was analyzed by flow cytometry. Results We found mixed tumors were ”cold” on a whole-tumor level. However, regional analysis showed a higher frequency of total and CD4 T cells in YFP regions compared to RFP regions. In contrast, macrophages exhibited a preferential localization to RFP regions. This suggests that local factors unique to each region drive the immune infiltration patterns of CD4 T cells and macrophages. Interestingly, although CD8 T cells showed a low frequency in all regions, a majority of CD8 T cells from YFP regions produced IFNgamma in response to PMA/Ionomycin stimulation while IFNgamma+ CD8 T cells from RFP regions made up a small fraction. This suggests that the presence of CF9-RFP regions inhibits infiltration of CD8 T cells throughout the tumor, but may not affect the anti-tumoral potential of CD8 T cells that succeed in infiltrating CF6-YFP regions. Conclusions An immunosuppressive tumor population rendered our model heterogeneous tumors ”cold” on the whole. Nonetheless, we observed regional patterns in the quantity and quality of immune infiltrates, with local immune infiltration being shaped by the tumor cells present in that region. Understanding how these immune infiltration patterns impact the response of each region to ICB therapy will provide insights into the mechanism by which ITH poses barriers to immunotherapy.
Safety Analysis of Pacritinib in Patients with Myelofibrosis and Severe Thrombocytopenia
Authors: John Mascarenhas, Claire N. Harrison, Aaron T. Gerds, Josef T. Prchal, Raajit Rampal, Sarah A Buckley, Adam R Craig, Jennifer A. Smith, John Volpone, Karisse Roman-Torres, Ruben A. Mesa
Journal: Blood (2021)
Tumor Junction Burden and Antigen Presentation as Predictors of Survival in Mesothelioma Treated With Immune Checkpoint Inhibitors
Authors: Farhad Kosari, Maria Disselhorst, Jun Yin, Tobias Peikert, Julia Udell, Sarah Johnson, James Smadbeck, Stephen Murphy, Alexa McCune, Giannoula Karagouga, Aakash Desai, Janet Schaefer-Klein, Mitesh J. Borad, John Cheville, George Vasmatzis, Paul Baas, Aaron S. Mansfield
Journal: Journal of Thoracic Oncology (2021)

The favorable outcomes with immunotherapy for mesothelioma were somewhat unexpected because this tumor has a low tumor mutation burden which has been associated with benefit in other cancers. Because chromosomal rearrangements are common in mesothelioma and have neoantigenic potential, we sought to determine whether they are associated with survival in patients treated with immunotherapy. Pleural biopsies of mesothelioma after at least one line of therapy were obtained from patients (n = 44) before treatment with nivolumab alone (NCT29908324) or in combination with ipilimumab (NCT30660511). RNA and whole-genome sequencing were performed to identify the junctions resulting from chromosomal rearrangements and antigen processing and presentation gene set expression. Associations with overall survival (OS) were estimated using Cox models. An OS cutoff of 1.5 years was used to distinguish patients with and without durable benefit for use in receiving operating characteristic curves. Although tumor junction burdens were not predictive of OS, we identified significant interactions between the junction burdens and multiple antigen processing and presentation gene sets. The "regulation of antigen processing and presentation of peptide antigen" gene set revealed an interaction with tumor junction burden and was predictive of OS. This interaction also predicted 1.5-year or greater survival with an area under the receiving operating characteristic curve of 0.83. This interaction was not predictive of survival in a separate cohort of patients with mesothelioma who did not receive immune checkpoint inhibitors. Analysis of structural variants and antigen presentation gene set expression may facilitate patient selection for immune checkpoint inhibitors.
A Preliminary Study on the Safety and Efficacy of a Novel Human BCMA-Targeting CAR-T Therapy in Patients with Relapsed/Refractory Multiple Myeloma
Authors: Yi Wang, Ying Gao, Hui Wang, Ding Zhang, Yan Zheng, Xingxing Hu, Qiuying Gao, Ben Niu, Hong Zhang, Wei Zhou, Weihua Zhang, Xingli Ru, Fangyuan Wang
Journal: Blood (2021)
Characteristics and Outcomes of Newly Diagnosed Multiple Myeloma Patients with and without Extramedullary Disease after Autologous Transplant and Maintenance Therapy: A Study from the Cmwp-EBMT
Authors: Nico Gagelmann, Dirk-Jan Eikema, Linda Koster, Tanja Netelenbos, Andrew McDonald, Anne-Marie Stoppa, Guido Kobbe, Achilles Anagnostopoulos, Gwendolyn Van Gorkom, Eric Deconinck, Claude-Eric Bulabois, Michel Delforge, Donald Bunjes, William Arcese, Péter Reményi, Maija Itälä-Remes, Lorenz Thurner, Zahit Bolaman, Yafour Nabil, Stephan Mielke, Hélène Labussière-Wallet, Patrick J Hayden, Meral Beksac, Stefan Schönland, Ibrahim Yakoub-Agha
Journal: Blood (2021)